Acaluxen 100 mg (Acalabrutinib): Uses, Dosage, Side Effects & More
Acaluxen 100 mg (Acalabrutinib): Uses, Dosage, Side Effects & Safety
Acaluxen 100 mg contains acalabrutinib, an oral targeted anticancer medicine belonging to the class of Bruton’s tyrosine kinase (BTK) inhibitors. It is used for specific adult patients with certain B-cell blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), depending on the treatment setting and applicable regulatory approval.
Acaluxen 100 mg is listed in the supplied product catalogue as a 60-capsule product containing acalabrutinib as the generic medicine.
Unlike conventional chemotherapy that can affect many rapidly dividing cells, acalabrutinib is a molecularly targeted medicine designed to interfere with a specific signalling protein involved in the development and survival of malignant B cells.
Treatment with acalabrutinib should be initiated and supervised by a physician experienced in the use of anticancer medicines.
What Is Acaluxen 100 mg?
Acaluxen 100 mg is a product containing acalabrutinib, a selective BTK inhibitor.
BTK is an important signalling protein within B cells. It participates in pathways associated with B-cell receptor signalling, cell proliferation, movement, adhesion and survival. In certain B-cell malignancies, these signalling pathways contribute to the persistence and growth of abnormal cells.
Acalabrutinib blocks BTK activity and therefore interferes with signalling that malignant B cells may depend upon.
The supplied product information identifies:
- Product Name: Acaluxen 100 mg
- Generic Name: Acalabrutinib
- Strength: 100 mg
- Dosage Form: Capsules
- Pack Size: 60 capsules
Regulatory product information for acalabrutinib also identifies 100 mg as the standard strength and recommends a 100 mg dose approximately every 12 hours in approved adult treatment settings.
What Is Acalabrutinib Used For?
Acalabrutinib is used for selected adult patients with certain B-cell malignancies.
Current regulatory information includes treatment of:
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL) in applicable regulatory settings
- Mantle cell lymphoma (MCL) in specific treatment situations
In the European Union, acalabrutinib is authorised for previously untreated CLL as monotherapy or in certain combinations, previously treated CLL, and specified mantle cell lymphoma settings.
The U.S. FDA labeling includes treatment of adult patients with CLL/SLL and specified MCL indications, including previously treated MCL and, in combination with bendamustine and rituximab, previously untreated MCL in adults who are not eligible for autologous hematopoietic stem-cell transplantation.
Because approved indications can vary between countries, treatment decisions should always follow the applicable local prescribing information.
Patient-Friendly Explanation
Acalabrutinib is a targeted cancer medicine used against certain cancers of B lymphocytes.
It works by blocking a protein called BTK, which helps abnormal B cells receive signals needed for growth and survival.
Medical Explanation
Acalabrutinib is a small-molecule BTK inhibitor. It binds covalently to a cysteine residue in the BTK active site and inhibits BTK enzymatic activity. BTK participates in B-cell receptor and cytokine-receptor signalling pathways that regulate B-cell proliferation, trafficking, chemotaxis and adhesion.
How Does Acalabrutinib Work?
Acalabrutinib works by targeting Bruton’s tyrosine kinase (BTK).
BTK is part of the signalling network that helps B lymphocytes respond to external signals. In certain B-cell cancers, abnormal signalling through this pathway can contribute to cancer-cell survival and proliferation.
A simplified pathway is:
B-cell receptor signalling → BTK activation → downstream signalling → B-cell growth and survival
Acalabrutinib acts by inhibiting BTK:
Acalabrutinib → BTK inhibition → reduced downstream signalling → reduced malignant B-cell signalling
Acalabrutinib and its active metabolite form a covalent bond with a cysteine residue within BTK's active site. This inhibits the enzyme and interferes with BTK-dependent signalling.
BTK signalling is associated with several biological processes, including:
- B-cell proliferation
- B-cell survival
- Cellular migration
- Chemotaxis
- Adhesion
- B-cell receptor signalling
By disrupting these pathways, acalabrutinib can reduce signalling that supports malignant B-cell activity.
The therapeutic objective is not to eliminate every cancer cell immediately. Rather, targeted inhibition is intended to suppress disease-driving biology and help control the malignancy.
Acalabrutinib is therefore classified as a targeted therapy, rather than conventional nonspecific cytotoxic chemotherapy.
Key Indications
Chronic Lymphocytic Leukemia
Acalabrutinib is used for eligible adults with CLL in several approved treatment settings.
Patient-friendly explanation:
CLL is a blood cancer involving abnormal B lymphocytes. Acalabrutinib targets BTK signalling inside these cells.
Medical explanation:
By inhibiting BTK, acalabrutinib interferes with B-cell receptor signalling involved in malignant B-cell survival and proliferation.
Small Lymphocytic Lymphoma
SLL is closely related to CLL, with the malignant lymphocytes predominantly involving lymphoid tissues.
Acalabrutinib may be used in applicable regulatory settings for adult patients with SLL.
Mantle Cell Lymphoma
Acalabrutinib has approved uses in specific adult MCL treatment settings.
The exact treatment approach depends on whether the disease is newly diagnosed, previously treated, relapsed or refractory, and whether the patient meets criteria for combination therapy or transplantation.
Acaluxen 100 mg Dosage and Administration
The appropriate dose must be determined by the treating physician.
For the current FDA-approved product information, the recommended adult dose is:
100 mg orally approximately every 12 hours.
The EMA product information likewise specifies 100 mg twice daily, equivalent to 200 mg per day.
Administration Instructions
- Take acalabrutinib exactly as prescribed.
- The dose is generally taken approximately 12 hours apart.
- Depending on the formulation and applicable product information, it may be taken with or without food.
- Swallow the medicine as instructed by the applicable product information.
- Do not change the dose without medical advice.
- Do not discontinue treatment independently.
- Treatment should be supervised by an experienced cancer specialist.
Dose Adjustments
Dose interruption or reduction may be necessary if certain adverse reactions occur or if clinically important drug interactions are present.
Missed Dose
If a dose is missed, patients should follow the instructions supplied with their specific product or contact their healthcare professional.
Do not automatically take a double dose to compensate for a missed dose.
Acalabrutinib Side Effects
Acalabrutinib can cause adverse reactions, and the likelihood and severity may differ among patients.
Common Side Effects
Commonly reported adverse reactions include:
- Upper respiratory tract infection
- Diarrhea
- Headache
- Musculoskeletal pain
- Fatigue
- Bruising
- Nausea
- Anaemia
The FDA identifies upper respiratory tract infection, diarrhea, headache and musculoskeletal pain among the most common adverse reactions.
Less Common Side Effects
Other clinically relevant effects may include:
- Low platelet counts
- Low neutrophil counts
- Low lymphocyte counts
- Bleeding
- Liver enzyme abnormalities
- Infections
- Muscle or joint discomfort
- Cardiac rhythm abnormalities
Serious Side Effects
Important serious risks include:
- Serious infections
- Major bleeding
- Significant cytopenias
- Cardiac arrhythmias
- Liver toxicity
- Drug-induced liver injury
- Second primary malignancies
These risks are specifically highlighted in current FDA prescribing information.
When to Seek Medical Attention
Urgent medical evaluation may be necessary if a patient develops:
- Severe or uncontrolled bleeding
- Blood in vomit, urine or stool
- Severe weakness or dizziness
- Fever or signs of serious infection
- New or worsening shortness of breath
- Chest pain
- Palpitations or fainting
- Yellowing of the skin or eyes
- Severe abdominal symptoms
Drug Interactions
Acalabrutinib can interact with other medicines by changing its exposure or by increasing the risk of adverse effects.
Medicines Requiring Particular Attention
Important interaction categories include:
- Strong CYP3A inhibitors
- Moderate CYP3A inhibitors
- Strong CYP3A inducers
- Acid-reducing medicines
- Medicines affecting bleeding risk
- Certain medicines affecting cardiac rhythm
Current FDA information recommends avoiding strong CYP3A inhibitors and strong CYP3A inducers and adjusting the dose when certain moderate CYP3A inhibitors are required.
Blood-Thinning Medicines
Because acalabrutinib can increase bleeding risk, patients taking:
- Anticoagulants
- Antiplatelet medicines
- Certain NSAIDs
should inform their healthcare professional.
The combination may require careful risk assessment and monitoring.
Food Considerations
Food instructions depend on the specific formulation and applicable product information.
Patients should follow the directions provided with their particular acalabrutinib product.
Supplement Considerations
Tell the healthcare provider before taking:
- St John's wort
- Herbal medicines
- Traditional medicines
- High-dose supplements
- Unregulated cancer supplements
Herbal and dietary products can affect drug metabolism or treatment safety.
Warnings and Precautions
Bleeding Risk
Acalabrutinib can increase the risk of hemorrhage.
Patients should report unusual bruising, prolonged bleeding, blood in stool or urine, coughing blood, or other unexplained bleeding.
Extra caution may be necessary when acalabrutinib is used with anticoagulants or antiplatelet medicines.
Infection Risk
Serious and opportunistic infections can occur during treatment.
Patients should report persistent fever, chills, worsening cough or other symptoms suggesting infection. The FDA recommends monitoring for signs and symptoms of infection and treating infections promptly.
Cardiovascular Considerations
Acalabrutinib has been associated with cardiac arrhythmias.
Patients should report:
- Palpitations
- Irregular heartbeat
- Dizziness
- Fainting
- New chest discomfort
Liver Considerations
Acalabrutinib can cause hepatotoxicity, including drug-induced liver injury.
Liver function may need to be monitored during treatment.
Blood Count Monitoring
Acalabrutinib may cause cytopenias, including reductions in:
- Neutrophils
- Platelets
- Haemoglobin
- Lymphocytes
Regular complete blood counts may therefore be required.
Second Primary Malignancies
Second primary malignancies, including skin cancers and other solid tumours, have been reported.
Patients should follow appropriate skin-protection measures and discuss unusual skin changes with their healthcare provider.
Pregnancy and Breastfeeding
Acalabrutinib may cause fetal harm and should not be used during pregnancy unless specifically determined appropriate by the treating physician.
Women who may become pregnant should discuss effective contraception with their healthcare professional.
Pregnancy planning should be discussed with the treating oncology team before treatment begins.
Breastfeeding is not recommended during treatment with acalabrutinib according to current FDA product information.
Special Populations
Elderly Patients
Older adults may use acalabrutinib when clinically appropriate, but treatment should consider:
- Overall health
- Other medical conditions
- Kidney and liver function
- Concomitant medicines
- Bleeding risk
- Infection risk
Pediatric Patients
Acalabrutinib is not routinely used as an adult treatment extrapolated to children. Pediatric use should follow approved indications and specialist oncology guidance.
Renal Impairment
Patients with impaired kidney function should inform their physician before starting treatment.
The clinical team can determine whether additional monitoring or treatment adjustments are required.
Hepatic Impairment
Liver impairment is particularly relevant because acalabrutinib is associated with hepatic adverse effects.
Current U.S. prescribing information advises avoiding acalabrutinib in patients with severe hepatic impairment.
Storage of Acaluxen 100 mg
Store Acaluxen 100 mg according to the storage instructions printed on the product packaging and applicable official product information.
General precautions include:
- Keep the medicine in its original packaging.
- Store away from excessive heat and moisture.
- Keep out of direct environmental exposure where applicable.
- Keep out of reach of children.
- Do not use damaged or visibly altered capsules.
- Follow the specific storage temperature stated on the product label.
Frequently Asked Questions About Acaluxen 100 mg
1. What is Acaluxen 100 mg used for?
Acaluxen 100 mg contains acalabrutinib and is intended for specific adult patients with certain B-cell cancers, including CLL and selected mantle cell lymphoma treatment settings.
2. What is acalabrutinib?
Acalabrutinib is an oral targeted anticancer medicine that inhibits Bruton’s tyrosine kinase (BTK).
3. Is acalabrutinib chemotherapy?
Acalabrutinib is generally classified as a targeted therapy rather than conventional cytotoxic chemotherapy.
4. How does acalabrutinib work?
It blocks BTK, a signalling protein involved in B-cell receptor pathways that support B-cell proliferation, migration and survival.
5. What is the usual dose of acalabrutinib?
The current FDA and EMA product information recommends 100 mg approximately every 12 hours for approved adult treatment settings, although treatment combinations and dose modifications may vary.
6. Can acalabrutinib be taken with food?
The current FDA labeling allows administration with or without food. Patients should follow the instructions for their specific formulation.
7. What are common acalabrutinib side effects?
Common adverse reactions include upper respiratory tract infection, diarrhea, headache and musculoskeletal pain.
8. Can acalabrutinib cause bleeding?
Yes. Hemorrhage is an important warning associated with acalabrutinib, particularly when other medicines that increase bleeding risk are also being used.
9. Can acalabrutinib affect blood counts?
Yes. Cytopenias can occur, so regular blood-count monitoring may be required.
10. Can acalabrutinib cause liver problems?
Yes. Hepatotoxicity, including drug-induced liver injury, is a recognized safety concern.
11. Can acalabrutinib cause infections?
Yes. Serious and opportunistic infections have been reported, so new infection symptoms should be assessed promptly.
12. Can acalabrutinib affect heart rhythm?
Yes. Cardiac arrhythmias can occur, so symptoms such as palpitations, dizziness or fainting should be reported.
13. Is acalabrutinib used for leukemia?
Yes. Acalabrutinib is used for adult patients with chronic lymphocytic leukemia in approved treatment settings.
14. Is acalabrutinib used for lymphoma?
Yes. It has approved uses in specific adult mantle cell lymphoma settings.
15. Can everyone with leukemia or lymphoma take acalabrutinib?
No. Treatment depends on the specific diagnosis, disease characteristics, previous treatment, other medical conditions and applicable regulatory indications.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and high-value medicines.
Our medicine-information resources are designed to help visitors understand:
- Generic medicines
- Brand and product information
- Therapeutic classes
- Uses and indications
- Dosage information
- Safety considerations
- Drug interactions
- Specialty oncology medicines
- Prescription-related information
- International medicine information
For medicines such as acalabrutinib, treatment should be managed by a qualified oncology professional. RootAid Pharma can provide medicine-related information and supply assistance where legally and operationally applicable.
Availability, prescription requirements, import rules, registration status and supply conditions can vary by country. These factors should be confirmed before a medicine is supplied, imported or used.
RootAid Pharma does not replace a physician, oncologist or pharmacist and does not claim to manufacture Acaluxen or acalabrutinib.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.